Michael S. Frontiera

626 total citations
10 papers, 455 citations indexed

About

Michael S. Frontiera is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael S. Frontiera has authored 10 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael S. Frontiera's work include Colorectal Cancer Treatments and Studies (2 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Research Studies (2 papers). Michael S. Frontiera is often cited by papers focused on Colorectal Cancer Treatments and Studies (2 papers), Cancer Treatment and Pharmacology (2 papers) and Lung Cancer Research Studies (2 papers). Michael S. Frontiera collaborates with scholars based in United States and United Kingdom. Michael S. Frontiera's co-authors include Paul J. Catalano, Mark Allen O’Rourke, John S. Macdonald, Don V. Jackson, Daniel G. Haller, Robert J. Mayer, Sally P. Stabler, J F Kolhouse, Robert H. Allen and David S. Ettinger and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Michael S. Frontiera

10 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael S. Frontiera United States	7	335	100	93	88	48	10	455
Francesca Fioretti Italy	13	252 0.8×	76 0.8×	89 1.0×	71 0.8×	100 2.1×	18	547
Ann G. Schwartz United States	4	142 0.4×	52 0.5×	106 1.1×	71 0.8×	57 1.2×	5	369
David Farrugia United Kingdom	10	236 0.7×	48 0.5×	150 1.6×	52 0.6×	110 2.3×	29	429
M Bertrand United States	8	280 0.8×	80 0.8×	82 0.9×	95 1.1×	78 1.6×	14	392
Teruyuki Ikehara Japan	10	247 0.7×	139 1.4×	68 0.7×	147 1.7×	97 2.0×	49	439
Wanli Liu China	11	244 0.7×	59 0.6×	87 0.9×	78 0.9×	40 0.8×	18	392
Frank J. Panettiere United States	11	225 0.7×	76 0.8×	114 1.2×	100 1.1×	55 1.1×	21	371
V. Rodriguez United States	8	162 0.5×	44 0.4×	111 1.2×	35 0.4×	60 1.3×	18	395
Johannes C. Nunnink United States	6	96 0.3×	83 0.8×	59 0.6×	34 0.4×	21 0.4×	6	303
Kou Nagasako Japan	14	318 0.9×	189 1.9×	209 2.2×	343 3.9×	67 1.4×	61	651

Countries citing papers authored by Michael S. Frontiera

Since Specialization

Citations

This map shows the geographic impact of Michael S. Frontiera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Frontiera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Frontiera more than expected).

Fields of papers citing papers by Michael S. Frontiera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Frontiera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Frontiera. The network helps show where Michael S. Frontiera may publish in the future.

Co-authorship network of co-authors of Michael S. Frontiera

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Frontiera. A scholar is included among the top collaborators of Michael S. Frontiera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Frontiera. Michael S. Frontiera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Brufsky, Adam, Karen Hoelzer, Thaddeus Beck, et al.. (2011). A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer. 11(4). 211–220. 25 indexed citations

Landry, Jerome C., Paul J. Catalano, John Hoffman, et al.. (2006). 2111. International Journal of Radiation Oncology*Biology*Physics. 66(3). S272–S272. 3 indexed citations

Haller, Daniel G., Paul J. Catalano, John S. Macdonald, et al.. (2005). Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. Journal of Clinical Oncology. 23(34). 8671–8678. 268 indexed citations

Dutcher, Janice P., et al.. (1995). A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group.. PubMed. 9(10). 1638–42. 6 indexed citations

Frontiera, Michael S., Sally P. Stabler, J F Kolhouse, & Robert H. Allen. (1994). Regulation of methionine metabolism: Effects of nitrous oxide and excess dietary methionine. The Journal of Nutritional Biochemistry. 5(1). 28–38. 36 indexed citations

Ettinger, David S., Dianne M. Finkelstein, Martin D. Abeloff, et al.. (1992). Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With Extensive-Stage Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized Study. JNCI Journal of the National Cancer Institute. 84(14). 1077–1084. 38 indexed citations

Grem, Jean L., Peter J. O’Dwyer, Paul Elson, et al.. (1991). Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.. Journal of Clinical Oncology. 9(10). 1793–1800. 13 indexed citations

Schiller, Joan H., et al.. (1989). Randomized Phase II-III Trial of Combination Beta and Gamma Interferons and Etoposide and Cisplatin in Inoperable Non-Small Cell Cancer of the Lung. JNCI Journal of the National Cancer Institute. 81(22). 1739–1743. 20 indexed citations

Frontiera, Michael S., James L. Murray, L. Lamki, et al.. (1989). Sequential Use of lndium-111 Labeled Monoclonal Antibodies 96.5 and ZME-018 does not Increase Detection Sensitivity for Metastatic Melanoma. Clinical Nuclear Medicine. 14(5). 357–366. 4 indexed citations

10.

Frontiera, Michael S., et al.. (1987). Peripheral blood and bone marrow abnormalities in the acquired immunodeficiency syndrome.. PubMed. 147(2). 157–60. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact